Treatments in evaluation;Thérapeutiques immunomodulatrices innovantes en cours d'évaluation

Annales de Dermatologie et de Venereologie

Volumn 132, Issue SPEC. ISS. 2, 2005, Pages

  Abou Samra, T ^a   Viraben, R ^b   D'Incan, M ^a  

^a HÔTEL DIEU   (France)

^b Serv Univ Psychiat l'Enfant l'A   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; BEXAROTENE; CD52 ANTIBODY; DENILEUKIN DIFTITOX; GAMMA INTERFERON; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 12; UNCLASSIFIED DRUG; VISILIZUMAB;

AUTOIMMUNITY; CYTOKINE PRODUCTION; CYTOTOXICITY; EVALUATION; HEMOLYTIC ANEMIA; HUMAN; IMMUNOMODULATION; SHORT SURVEY;

HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS;

EID: 25144444174     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (17)

1. Dereure O, Levi E, Vonderheid EC, Kadin ME. Infrequent Fas mutations but no Bax or P53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes un the skin. J Invest Dermatol 2002:;18:949-56.
2. Rook AH, Vowels BR, Jaworsky C, Singh A, Lessin SR. The immunopathogenesis of cutaneous T-cell lymphoma. Abnormal cytokine production by Sézary T cells. Arch Dermatol 1993;129:486-9.
3. Vowells BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production by Sézary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992;99:90-4.
4. Asadullah K, Docke WD, Haeussler A, Sterry W, Volk HD. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 1996;107:833-7.
5. Rook AH, Zaki MH, Wysocka M, Wood GS, Duvic M, Showe LC, et al. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci 2001;941:177-84.
6. Dalloul A Laroche L, Bagot M, Mossalayi MD, Fourcade C, Thacker DJ, et al. Interleukin-7 is a growth factor for Sézary lymphoma cells. J Clin Invest 1992;90:1054-60.
7. Zucker-Franklin D. The role of interleukin-7 and interleukin-15 in cutaneous T-cell lymphoma. Blood 2002;99:3488.
8. LeMaistre CF, Mansoor N, Saleh SH, Timothy M, Kuzel K, Foss F, et al. Phase I Trial of a Ligand Fusion-Protein (DAB38gIL-2) in Lymphomas Expressing the Receptor for Interkeukin-2. Blood 1998;91:399-405.
9. Saleh MN, LeMaistre CF, Kuzel TM, Foss F, Platanias LC, Schwartz G, et al. Antitumor activity of DAB38gIL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 1998;39:63-73.
10. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-88.
11. Sidell N, Kummer U, Aframian D, Thierfelder S. Retinoid regulation of interleukin-2 receptors on human T-cells. Cell Immunol 1997;179:116-25.
12. Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin difitox. Blood 2002;15:1399-403.
13. Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood 2003;101:4267-72.
14. Knox S, Hoppe RT, Maloney D, Gibbs I, Fowler S, Marquez C, Cornbleet PJ, Levy R. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 1996;87:893-9.
15. Dummer R, Hassel JC, Fellenberg F, Eichmuller S, Maier T, Slos P, et al. Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 2004;104:1631-8.
16. Didona B, Benucci R, Amerio P, Canzona F, Rienzo O, Cavalieri R. Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara). Br J Dermatol 2004;150:1198-201.
17. Beyeler M, Dummer R. Standard and experimental therapy of cutaneous T-cell lymphoma. Hautarzt 2003;54:1177-84.